The US FDA has been on a roll this month with approving cancer drugs ahead of schedule, with the latest being Seattle Genetics' Adcetris (brentuximab vedotin), the first therapy in 34 years available to treat patients with Hodgkin’s lymphoma (HL) – coming 11 days early, triggering a 14.2% jump in the Bothell, Washington-based biotech's stock on 19 August.
The drug also won a second indication of systemic anaplastic large cell lymphoma (ALCL), a rare T-cell non-Hodgkin’s lymphoma with...